adminUnknown Analyst
Good afternoon, everyone. Welcome to the day 1 of Bank of America Healthcare Conference in London. My name is [ Lu ], and I am part of the U.S. Life Science tools. And we are very fortunate to have Jeff Simmons with Elanco Animal Health, President and CEO. And I guess maybe Jeff has some opening statement to begin with, and then we do go up there.
Jeffrey Simmons
President, CEO & Director
Yes. Obviously, note the disclaimers that we normally do in a conference like this, thanks to Bank of America. It’s been great to be in Europe with a lot of our customers and traveling to a lot of our operations here, and to be able to have the opportunity here with investors. So thanks for the interest. I would just make a couple of comments. I mean we noted our 8-year anniversary as an independent company coming out of Lilly on Friday. It’s been a very intentional journey as we’ve stood up as we’ve acquired Bayer, so we built an omnichannel, build a pipeline. We’ve been very focused the last 3 years, especially on growth, innovation, cash.
We just finished a great quarter, where we delivered 10% reported growth that came from Farm, Pet for a 50-50 split. U.S. international, 50-50 price volume. So we really had high-quality growth that came from the quarter. I think the second priority is all around innovation. We’ve got a basket of 6 innovations, 6 blockbuster products that are in big markets where we’re in early days, but we have a clear differentiation. We believe medical differentiation that’s taking really great share, Zenrelia, Quattro, Experior across a lot of markets. And now as I’m out here
Read the full article here
